Sugi Predict

Sugi Predict / Compounds / SCHEMBL29429587

SCHEMBL29429587

SCHEMBL29429587

CC[C@H](C)[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCCN)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)O

nearest known ligand 0.64

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
▸ PTH1R Q03431 11/20 0.64
▸ KEAP1 Q14145 3/20 0.63
▸ IL23R Q5VWK5 1/20 0.58
▸ RXFP1 Q9HBX9 1/20 0.57
▸ GLP1R P43220 2/20 0.57
▸ GCGR P47871 1/20 0.57
▸ GIPR P48546 1/20 0.57
▸ GHSR Q92847 2/20 0.57
▸ NPY2R P49146 1/20 0.57
▸ CCKBR P32239 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29350300 1.00 PTH1R (0.64) PTH1RKEAP1IL23RRXFP1GLP1R
SCHEMBL30617122 0.97 PTH1R (0.61) PTH1RKEAP1IL23RGLP1RGCGR
Penetratin SCHEMBL29356568 0.97 PTH1R (0.66) PTH1RKEAP1IL23RRXFP1GHSR
SCHEMBL30002139 0.96 PTH1R (0.63) PTH1RKEAP1IL23RRXFP1GLP1R
SCHEMBL30299196 0.95 PTH1R (0.67) PTH1RKEAP1IL23RRXFP1GLP1R
SCHEMBL29710643 0.95 PTH1R (0.65) PTH1RKEAP1IL23RRXFP1GHSR
Penetratin SCHEMBL29450548 0.94 KEAP1 (0.64) PTH1RKEAP1IL23RRXFP1GLP1R
SCHEMBL31749000 0.94 PTH1R (0.63) PTH1RKEAP1IL23RRXFP1GLP1R
SCHEMBL31232534 0.93 PTH1R (0.68) PTH1RKEAP1IL23RRXFP1GLP1R
SCHEMBL30082489 0.93 PTH1R (0.58) PTH1RKEAP1IL23RRXFP1GLP1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12552846-B2 Modified BCL9 mimetic peptides Sapience Therapeutics, Inc. (US) 2026-02-17 — — US disclosed
US-20250127849-A1 ATF5 Peptide Variants and Uses Thereof Sapience Therapeutics, Inc. 2025-04-24 — — US disclosed
CN-113845581-B ATF5 peptide variants and uses thereof 智慧疗法有限公司 2025-03-21 — — CN disclosed
US-12208131-B2 ATF5 peptide variants and uses thereof Sapience Therapeutics, Inc. (US) 2025-01-28 — — US disclosed
US-20240263159-A1 GENE EDITING IN PRIMARY IMMUNE CELLS USING CELL PENETRATING CRISPR-CAS SYSTEM THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA 2024-08-08 — — US disclosed
US-20240181003-A1 ATF5 Peptide Variants and Uses Thereof Sapience Therapeutics, Inc. 2024-06-06 — — US disclosed
US-11878047-B2 ATF5 peptide variants and uses thereof Sapience Therapeutics, Inc. (US) 2024-01-23 — — US disclosed
EP-4275757-A2 ATF5 PEPTIDE VARIANTS AND USES THEREOF Sapience Therapeutics, Inc. (US) 2023-11-15 — — EP disclosed
US-20230248837-A1 Technology for Modulating Targeting Chimeras Induced by Cell-Penetrating Peptide and Application Thereof LIU, MIAO (CN) 2023-08-10 — — US disclosed
WO-2023143777-A1 PEPTIDE-BASED SYNTHETIC CHLORIDE ION TRANSPORTERS TAVANTA THERAPEUTICS HUNGARY INCORPORATED (HU) 2023-08-03 — — WO disclosed
US-20230066049-A1 PEPTIDES USEFUL IN PRESERVATION AND/OR RESTORATION OF FUNCTIONAL PANCREATIC ISLETS AND IN TREATING DIABETES NAT INST BIOTECHNOLOGY NEGEV LTD (IL) 2023-03-02 — — US disclosed
EP-4096697-A1 PEPTIDES USEFUL IN PRESERVATION AND/OR RESTORATION OF FUNCTIONAL PANCREATIC ISLETS AND IN TREATING DIABETES The National Institute for Biotechnology in the Negev Ltd. (IL) 2022-12-07 — — EP disclosed
US-20220287968-A1 LIPID VESICLE-MEDIATED DELIVERY TO CELLS FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC. 2022-09-15 — — US disclosed
US-20220275036-A1 Modified BCL9 Mimetic Peptides Sapience Therapeutics, Inc. 2022-09-01 — — US disclosed
US-20220265843-A1 EXTRACELLULAR VESICLE-MEDIATED DELIVERY TO CELLS FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC. 2022-08-25 — — US disclosed
US-11407789-B2 Cell-penetrating compstatin analogs and uses thereof APELLIS PHARMACEUTICALS, INC. (US) 2022-08-09 — — US disclosed
EP-3994160-A1 MODIFIED BCL9 MIMETIC PEPTIDES Sapience Therapeutics, Inc. (US) 2022-05-11 — — EP disclosed
CN-108350046-B Analogs of VDAC 1-derived peptides 在本-古里安大学的B．G．内盖夫科技与应用有限公司 2022-04-01 — — CN disclosed
US-20220088131-A1 COMPOSITIONS AND METHODS RELATING TO C5L2 KING'S COLLEGE LONDON (GB) 2022-03-24 — — US disclosed
CN-114144424-A Modified BCL9 mimetics 智慧疗法有限公司 2022-03-04 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12552846-B2 Modified BCL9 mimetic peptides BCL9, BCL9L, BCL2L2 PTH1R 1347/4885KEAP1 4811/4885IL23R 2523/4885
US-11407789-B2 Cell-penetrating compstatin analogs and uses thereof C9, C3AR1, SERPINC1 PTH1R 838/4885KEAP1 2738/4885IL23R 2240/4885
US-20230248837-A1 Technology for Modulating Targeting Chimeras Induced by Cell-Penetrating Peptide and Application Thereof VIP, GHITM, MYCBP PTH1R 2477/4885KEAP1 4066/4885IL23R 1842/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback